US Stock MarketDetailed Quotes

DAWN Day One Biopharmaceuticals

Watchlist
  • 12.260
  • +0.050+0.41%
Close Feb 14 16:00 ET
  • 12.500
  • +0.240+1.96%
Post 20:01 ET
1.24BMarket Cap-12.64P/E (TTM)

About Day One Biopharmaceuticals Company

Day One Biopharmaceuticals, Inc. operates as a holding company. The firm through its subsidiary develops and commercializes targeted therapies for patients of all ages with genetically defined cancers. Its products include DAY101 and pimsertib. The company was founded by Julie Grant and Samuel Blackman in November 2018 and is headquartered in Brisbane, CA.

Company Profile

SymbolDAWN
Company NameDay One Biopharmaceuticals
Listing DateMay 27, 2021
Issue Price16.00
Founded2018
CEODr. Jeremy Bender
MarketNASDAQ
Employees155
Fiscal Year Ends12-31
Address2000 Sierra Point Parkway,Suite 501
CityBrisbane
ProvinceCalifornia
CountryUnited States of America
Zip Code94005
Phone1-650-484-0899

Company Executives

  • Name
  • Position
  • Salary
  • Dr. Jeremy Bender
  • Chief Executive Officer, President and Director
  • 6.91M
  • Adam Dubow
  • General Counsel and Chief Compliance Officer
  • 2.77M
  • Charles N. York, II
  • Principal Accounting Officer, Chief Operating Officer, Chief Financial Officer and Secretary
  • 3.55M
  • Garry A. Nicholson
  • Chairman of the Board
  • 383.38K
  • Habib Joseph Dable
  • Director
  • --
  • Dr. William Grossman
  • Director
  • --
  • Saira Ramasastry, M.Phil,M.S.
  • Independent Director
  • 351.75K
  • Scott Garland
  • Independent Director
  • 342.88K
  • Michael Gladstone
  • Independent Director
  • 342.88K
  • Dr. John A. Josey, PhD
  • Independent Director
  • 350.75K
  • Natalie C. Holles
  • Lead Independent Director
  • 352.50K
  • Dr. Samuel Blackman, M.D.
  • Head of Research and Development
  • 2.49M

Trending Stocks

Discussing
Trump 2.0 Era: How will global markets evolve?
🎙️Discussion: 1. How will tariff policies affect the movement of key assets such as U.S. stocks, gold, and Bitcoin? 2. Given this context, Show More
Reassessing Chinese Assets
Following the introduction of China's groundbreaking DeepSeek technology, Wall Street giants have revised their investment outlooks for the Chinese market.